Somatostatin receptor scintigraphy with 111In-pentetreotide in non-functioning gastroenteropancreatic neuroendocrine tumors

  • Authors:
    • Orazio Schillaci
    • Angela Spanu
    • Francesco Scopinaro
    • Antonio Falchi
    • Vito Corleto
    • Roberta Danieli
    • Pietro Marongiu
    • Nicola Pisu
    • Giordano Madeddu
    • Gianfranco Delle Fave
    • Giuseppe Madeddu
  • View Affiliations

  • Published online on: December 1, 2003     https://doi.org/10.3892/ijo.23.6.1687
  • Pages: 1687-1695
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

To investigate somatostatin receptor scintigraphy (SRS) usefulness compared to conventional imaging procedures (CIP) in non-functioning gastroenteropatic (GEP) neuroendocrine tumors, we studied 40 patients, 30 in follow-up (FU) after previous operation for primary tumor (27 cases) or non-operable for disseminated metastases (3 cases), and 10 in the phase of initial diagnosis and staging (IDS). All patients were asymptomatic for hormone overexpression, with slightly high serum chromogranine A in 6 FU. The definitive diagnosis was obtained by surgery, laparotomy or percutaneous CT/US guided biopsy. Within 1 month before scintigraphy, all patients had undergone at least 2 of 3 CIP (CT, MRI and US); 4 and 24 h after 250 MBq 111In-pentetreotide i.v. injection, whole body scanning, planar and SPECT over the abdomen or other suspect regions were performed. Globally, 135 neoplastic lesions (84 hepatic, 34 abdominal extra-hepatic and 17 extra-abdominal) were ascertained in 32/40 patients; SPECT was positive in 29 cases, CIP in 28 and planar in 20, while all 3 procedures were true negative in the remaining 8 cases. Per patient sensitivity and accuracy were significantly higher at SPECT and CIP than planar. SPECT showed a significantly higher per lesion sensitivity (89.6%) than CIP (72.6%) and planar (53.3%) while CIP sensitivity was significantly higher than planar. SPECT correctly modified CIP patient classification and thus management in 18.7% of patients, while it downstaged the disease in 9.4% in respect of CIP; planar was incorrect in 51.3% of cases. SPECT and CIP combined use achieved 100% accuracy and correctly classified all patients. 111In-pentetreotide SRS, particularly SPECT, is a useful diagnostic tool in the detection of non-functioning GEP tumors, contributing to correct patient classification and appropriate therapeutic strategy. SPECT proved more sensitive than CIP, but their combined use achieved the highest accuracy values and gave the most accurate disease staging.

Related Articles

Journal Cover

December 2003
Volume 23 Issue 6

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Schillaci O, Spanu A, Scopinaro F, Falchi A, Corleto V, Danieli R, Marongiu P, Pisu N, Madeddu G, Delle Fave G, Delle Fave G, et al: Somatostatin receptor scintigraphy with 111In-pentetreotide in non-functioning gastroenteropancreatic neuroendocrine tumors. Int J Oncol 23: 1687-1695, 2003
APA
Schillaci, O., Spanu, A., Scopinaro, F., Falchi, A., Corleto, V., Danieli, R. ... Madeddu, G. (2003). Somatostatin receptor scintigraphy with 111In-pentetreotide in non-functioning gastroenteropancreatic neuroendocrine tumors. International Journal of Oncology, 23, 1687-1695. https://doi.org/10.3892/ijo.23.6.1687
MLA
Schillaci, O., Spanu, A., Scopinaro, F., Falchi, A., Corleto, V., Danieli, R., Marongiu, P., Pisu, N., Madeddu, G., Delle Fave, G., Madeddu, G."Somatostatin receptor scintigraphy with 111In-pentetreotide in non-functioning gastroenteropancreatic neuroendocrine tumors". International Journal of Oncology 23.6 (2003): 1687-1695.
Chicago
Schillaci, O., Spanu, A., Scopinaro, F., Falchi, A., Corleto, V., Danieli, R., Marongiu, P., Pisu, N., Madeddu, G., Delle Fave, G., Madeddu, G."Somatostatin receptor scintigraphy with 111In-pentetreotide in non-functioning gastroenteropancreatic neuroendocrine tumors". International Journal of Oncology 23, no. 6 (2003): 1687-1695. https://doi.org/10.3892/ijo.23.6.1687